Gastrointestinal Imaging: Digesting Change
by Judith Gunn Bronson
Protocols in gastrointestinal imaging are shifting with the introduction of MDCT, catheter-mounted ultrasound probes, new applications for MRI, and indications for FDG-PET.
Metastatic breast cancer lesion (a) disappears (right) due to improperly timed scan. In colon cancer patient, the consequences of delayed imaging are a fill-in from the periphery (b), leading to underestimation of lesion size. Images courtesy of Paul Silverman, MD, MD Anderson Cancer Center.
|
Demand for gastrointestinal imaging was long inhibited by the
accessibility of much of the tissue to endoscopy. Recently,
however, improvements in imaging technology and the drive to
minimally invasive (and lower cost) procedures has encouraged
recognition of gastrointestinal imaging as a specialty.1 Today,
endoscopy, including such traditional studies as retrograde
cholangiopancreatography, is being supplanted by radiologic studies
if the purpose is purely diagnostic. Further changes (and
uncertainty) can be expected as new technology comes online.
CT: An indispensAble tool
As in so many other areas of the body, CT is now the standard
examination for most gastrointestinal conditions, a dominance
brought about by greater scanner speed, the availability of
software for three-dimensional reconstruction, and oral contrast
agents. Helical CT "has changed radiologists' approach to liver
imaging."2 Small-bowel obstruction and ischemia are routinely
diagnosed by CT,3 which also is commonly used at some centers for
gastric and mesenteric angiography.3,4 Enteroclysis with CT has
become standard for imaging of the small bowel at many medical
centers because the optimal distention of the intestinal loops
improves the sensitivity and specificity, and CT allows close
examination of the bowel wall and the neighboring anatomy.5
Multidetector-array scanners, with their greater speed and
thinner collimation, have caused a further revolution in
gastrointestinal imaging, permitting higher-resolution images,
real-time three-dimensional reconstruction, and multiphasic studies
while virtually eliminating motion artifacts.4 One clear result is
superior assessment and staging of cancers.
At The University of TexasMD Anderson Cancer Center in Houston,
11 multidetector CT scanners perform 320 examinations per day.
"Every patient either comes to us having had a CT scan or has one
here," reports Paul M. Silverman, MD, professor of diagnostic
radiology and director of academic development at UTAnderson. "The
main considerations are the speed and comfort of the examination
and the ability to accommodate the large number of patients we see
and will continue to see as the Baby Boomers age. Imaging is
critical for patients with cancer, because the clinicians use the
images along with the histologic findings to select the treatment
regimen. And that is the point of coming to a cancer center: to
have your cancer staged accurately and get the best treatment for
your particular situation."
Optimizing MDCT protocols is a focus of radiology research at
UTAnderson. "Multidetector scanners permit us to detect lesions
more effectively, and contrast medium lets you see the lesions even
better. But this is assuming you use contrast appropriately. If you
do notif the scan is not timed properly in relation to contrast
deliveryyou can easily overlook lesions. It therefore is critical
for radiologists to know the features and basic contrast dynamics
of the target organ and where a particular type of cancer is most
likely to metastasize. For example, if you are looking for a
pancreatic tumor, your target is small, so you need thin slices.
Ovarian cancer spreads to the omentum, so you need to look there
very closely. In other words, you tailor your image acquisition and
your reading closely to the specific situation. It's a sort of
Willie Sutton rule: you spend your efforts where the moneyor, in
this case, the canceris." The UT-Anderson team has published a
series of articles on imaging of specific cancers,6-8 and Silverman
is the author of two books on protocols for helical9 and
multidetector-array CT.10
Ultrasonography: In flux
For gastrointestinal imaging, ultrasonography is largely an
adjunct to endoscopy. The introduction of 6F to 10F
catheter-mounted probes and linear-array echoendoscopes has
"revolutionized the diagnosis and treatment of gastrointestinal
diseases that affect the submucosal bowel wall and adjacent
extramural structures."11 High-resolution three-dimensional imaging
is now possible.12 Among the possibilities are measurement of
esophageal varices,12 evaluation of submucosal lesions12 or chronic
pancreatitis,13 and staging and resectability assessment of
esophageal, rectal, and pancreatic cancers.13,14 However, there are
questions about whether this invasive procedure is warranted when
endoscopic treatment is unlikely: the diagnostic information can
often be obtained now by cross-sectional imaging modalities.14
MRI: A growing role
For many years, the gastrointestinal tract was largely ignored
by MRI practitioners because its motion degraded the images.
Although MRI studies generally are too slow for routine use,
applications are growing, particularly to solve problems raised by
other modalities. In some medical centers, MR angiography is
considered the technique of choice for evaluating suspected
mesenteric ischemia, assessing the resectability of pancreatic
cancer, and evaluating the hepatic vasculature in potential living
related liver donors and liver transplant recipients.15
Cholangiography with MR has demonstrated utility in patients with
suspected obstruction, primary sclerosing cholangitis, and
inadequate endoscopic retrograde cholangiograms.1 Indeed, its
absence of ionizing radiation and the need for anesthesia, its
superior depiction of the biliary ducts proximal to an obstruction,
and its noninvasiveness make MR preferable to the classic
endoscopic study in many situations.1 Magnetic resonance studies
have a sensitivity and specificity exceeding 90% in the
identification of common bile duct stones, which are depicted
regardless of their chemical composition.1 Magnetic resonance
cholangiography can depict the dimensions of choledochal cysts and
is valuable for assessment and interventional planning in patients
with biliaryenteric anastomoses, in whom endoscopic studies are
difficult or impossible.1 Finally, MR cholangiography may be useful
in patients in whom endoscopic studies have failed or produced poor
results. In the view of D. Bradley Koslin, MD, of the Oregon Health
& Science University in Portland, MR cholangiography may well
become "the first-line examination of the biliary tree when a
therapeutic procedure is of low likelihood."1
The introduction of contrast agents is increasing the value of
MRI for the gastrointestinal tract. Oral agents are classified as
positive (ie, the lumen of the bowel appears bright), negative
(dark lumen), or biphasic (bright on T1-weighted images and dark on
T2-weighted images or vice versa).16 Availability of intravascular
contrast agents would enable MRI to be used for pinpointing the
source of gastrointestinal bleeding.14 A technique with reportedly
great promise for the assessment of inflammatory bowel disease is
hydro-MRI, in which a mannitol solution is used as an oral contrast
agent.17 The study provides "superior"17 images of the bowel wall,
permitting distinction of active inflammation from scarring and
examination of the extramural tissues. Hydro-MRI is more helpful in
Crohn's disease than in ulcerative colitis, which involves the
mucosa rather than the entire thickness of the wall.
Nuclear Medicine: Role for Pet?
The ability of positron emission tomography with fluorine
18-labeled deoxyglucose (FDG)-PET to identify tissues with high
metabolic rates (which often are malignant) permits identification
of many primary tumors and metastases. Approximately 20% of
patients with colorectal cancer have metastases at diagnosis, and the recurrence
rate after apparently curative resection is 30% to 40%, suggesting
a role for FDG PET. Although the study is not the preferred means
of diagnosis of the primary tumor, it is more sensitive than
helical CT in finding hepatic (89% to 95% versus 71% to 84%) and
extrahepatic (87% to 92% versus 71% to 86%) metastases.1 PET may
also have a role in patients with a high serum carcinoembryonic
antigen concentration and an occult primary tumor and has been used
in assessing operability; in one series of 249 patients, PET
revealed unexpected lesions that changed the treatment plan in
26%.1 Whether PET is superior to multidetector-array CT is not yet
clear. Two drawbacks of FDG-PET in evaluating colorectal cancer are
difficulty in identifying lesions smaller than 1 cm and the high
false-positive rate in the presence of inflammation, such as in
patients with diverticulitis.1
The Future
Some roles remain for traditional methods of gastrointestinal
imaging. The double-contrast barium study, with its ability to
illuminate fine mucosal detail, is valuable for the initial
diagnosis of ulcerative colitis or Crohn's disease.18 In this
situation, the cross-sectional imaging modalities have a
complementary role, depicting such pathology as intra-abdominal
abscesses. Double-contrast barium studies also are important at
some centers for the diagnosis of colorectal cancers,19 although
they are being displaced by virtual colonoscopy (reviewed elsewhere
in this issue). Yet another application of a classic technique is
the use of fluoroscopy to confirm and classify gastrointestinal
fistulas.20 Here again, cross-sectional studies are making
significant inroads.
The gastrointestinal tract appears to be an excellent subject
for molecular imaging. An interdisciplinary team at the University
of Vienna took advantage of the propensity of human tumors and
their blood vessels to overexpress the vascular endothelial growth
factor receptor.21 Those investigators labeled recombinant human
VEGF with iodine 123, administered it to 18 patients with known
gastrointestinal tumors, and acquired SPECT images 1.5 hours later.
Primary pancreatic cancers were imaged in seven of nine patients,
with lymph node, liver, and lung metastases being seen in several.
Half of the cholangiocarcinomas and hepatocellular carcinomas were
likewise depicted. Further work will be necessary to determine if
this technique will be useful for diagnosis or staging of
gastrointestinal cancers. Nuclear medicine studies using specific
labeled peptides,22 antibodies,22and oligonucleotides23 are being
tested clinically.
Conclusion
Changes in the protocols for gastrointestinal imaging seem
likely to continue. A new noninvasive option whose role is being
defined is capsule endoscopy. Its advantages are the short time the
patient remains at the hospital and its painlessness. The study may
prove especially useful for evaluating small bowel disease and
identifying the source of chronic or intermittent bleeding,
although it generally is not given to evaluate polyps or tumors
because of the risk of intestinal obstruction.24 Where this device
fits in and the relative roles of multidetector CT and PET or MRI
will not be known until more data become available.
Judith Gunn Bronson, MS, is a contributing writer for Decisions in Imaging Economics.
References:
- Koslin DB. Update on gastrointestinal imaging. Rev Gastroenterol Disord. 2002;2:3"10.
- Silverman PM, Kohan L, Ducic I, et al. Imaging of the liver with helical CT: a survey of scanning techniques. AJR Am J Roentgenol. 1998;170:149"152.
- Horton KM, Fishman EK. The current status of multidetector row CT and three-dimensional imaging of the small bowel. Radiol Clin North Am. 2003;41:199"212.
- Horton KM, Fishman EK. Volume-rendered 3D CT of the mesenteric vasculature: normal anatomy, anatomic variants, and pathologic conditions. Radiographics. 2002;22:161"172.
- Maglinte DD, Bender GN, Heitkamp DE, Lappas JC, Kelvin FM. Multidetector-row helical CT enteroclysis. Radiol Clin North Am. 2003;41:249"262.
- Kundra V, Silverman PM. Imaging in Oncology from the University of Texas M.D. Anderson Cancer Center: imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol. 2003;180:1045"1054.
- Iyer RB, Silverman PM, DuBrow RA, Charnsangavej C. Imaging in the diagnosis, staging, and follow-up of colorectal cancer. AJR Am J Roentgenol. 2002;179:3â€"13.
- Tamm EP, Silverman PM, Charnsangavej C, Evans DB. Diagnosis, staging, and surveillance of pancreatic cancer. AJR Am J Roentgenol. 2003;180:1311"1323.
- Silverman PM. Helical (Spiral) Computed Tomography: A Practical Approach to Clinical Protocols. Baltimore: Lippincott Williams & Wilkins, 1998.
- Silverman PM. Multislice Computed Tomography: Principles, Practice, and Clinical Protocols. Baltimore: Lippincott Williams & Wilkins, 2002.
- Sandu IS, Bhutani MS. Gastrointestinal endoscopic ultrasonography. Med Clin North Am. 2002;86:1289"1317.
- Liu JB, Miller LS, Bagley DH, Goldberg BB. Endoluminal sonography of the genitourinary and gastrointestinal tracts. J Ultrasound Med. 2002;21:323"337.
- Fickling WE, Wallace MB. Endoscopic ultrasound and upper gastrointestinal disorders. J Clin Gastroenterol. 2003;36:103"110.
- Dye CE, Waxman I. Endoscopic ultrasound. Gastroenterol Clin North Am. 2002;31:863"879.
- Hagspiel KD, Leung DA, Angle JF, et al. MR angiography of the mesenteric vasculature. Radiol Clin North Am. 2002;
- . Laghi A, Paolantonio P, Iafrate F, Altomari F, Miglio C, Passariello R. Oral contrast agents for magnetic resonance imaging of the bowel. Top Magn Reson Imaging. 2002;13:389"396.
- Schunk K. Small bowel magnetic resonance imaging for inflammatory bowel disease. Top Magn Reson Imaging. 2002;13:409"425.
- Carucci LR, Levine MS. Radiographic imaging of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:93"117.
- Elmas N, Killi RM, Sever A. Colorectal carcinoma: radiological diagnosis and staging. Eur J Radiol. 2002;42:206"223.
- Pickhardt PJ, Bhalla S, Balfe DM. Acquired gastrointestinal fistulas: classification, etiologies, and imaging evaluation. Radiology. 2002;224:9"23.
- Li S, Peck-Radosavljevic M, Kienast O, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF[165]) receptor scintigraphy. Ann Oncol. 2003;14:1274"1277.
- Moadel RM, Blaufox MD, Freeman LM. The role of positron emission tomography in gastrointestinal imaging. Gastroenterol Clin North Am. 2002;31:841"861.
- Tavitian B. In vivo imaging with oligonucleotides for diagnosis and drug development. Gut. 2003;52(Suppl 4):iv40"iv47.
- Rabenstein T, Krauss N, Hahn EG, Konturek P. Wireless capsule endoscopy: beyond the frontiers of flexible gastrointestinal endoscopy. Med Sci Monit. 2002;8:RA128"RA132.
 |
|
 |
|
|
 |
|